AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.
AJ Cannon, MD
Advertisement
Dr Cannon is a board-certified psychiatrist, physician-neuroscientist, and senior medical director in Neuroscience Clinical Development at AbbVie, where he designs and leads clinical trials evaluating novel treatments for serious mental illnesses.
Articles by AJ Cannon, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media
2
Paying Attention to the Psychopharmacology Pipeline
3
ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings
4
Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis
5